SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-17-218379
Filing Date
2017-06-29
Accepted
2017-06-29 16:29:02
Documents
5
Period of Report
2017-06-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d404244d8k.htm 8-K 19188
2 EX-1.1 d404244dex11.htm EX-1.1 144657
3 EX-5.1 d404244dex51.htm EX-5.1 7156
4 GRAPHIC g404244ex51logo1.jpg GRAPHIC 6831
5 GRAPHIC g404244ex51logo2.jpg GRAPHIC 2680
  Complete submission text file 0001193125-17-218379.txt   185522
Mailing Address 245 FIRST STREET SUITE 1100 CAMBRIDGE MA 02142
Business Address 245 FIRST STREET SUITE 1100 CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 17938659
SIC: 2834 Pharmaceutical Preparations